Hepatitis C Virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 20, Issue 4, 2004, Pages 351-353

  Soriano, Vincent ^a,b   Pérez Olmeda, Mayte ^a   Ríos, Pilar ^b   Núñez, Marina ^a   García Samaniego, Javier ^a   González Lahoz, Juan ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RELAPSE; TREATMENT WITHDRAWAL; VIRUS IDENTIFICATION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; VIREMIA;

EID: 2342458264     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204323048096     Document Type: Article

References (16)

1. Soriano V, Sulkowski M, Bergin C, et al.: Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813-828.
2. Manns M, McHutchison J, Gordon S, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001;358:958-965.
3. Fried M, Shiffman M, Reddy R, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
4. Hadziyannis S, Cheinquer H, Morgan T, et al.: Peginterferon alfa-2 a (Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and ribavirin dose. J Hepatol 2002;36(Suppl 1):1.
5. Nasti G, Di Gennaro G, Tavio M, et al.: Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 2001;15:1783-1787.
6. Landau A, Batisse D, Piketty C, et al.: Long-term efficacy of combination therapy with interferon alfa-2b plus ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001;15: 2149-2155.
7. Pérez-Olmeda M, Núñez M, Romero M, et al.: Pegylated interferon alpha plus ribavirin as therapy for chronic hepatitis C in HIV-coinfected patients. AIDS 2003;17:1023-1028.
8. Chung R, Andersen J, Alston B, et al.: A randomized, controlled trial of pegylated interferon alfa-2 a plus ribavirin vs interferon alfa-2 a plus ribavirin for the treatment of HCV in HIV coinfection: ACTG A5071. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002 (abstract LB15).
9. Goelz J, Klausen G, Moll A, et al.: Efficacy and tolerance of therapy with interferon alpha/ribavirin and pegIFN alpha//RBV in HIV/HCV-coinfected IVDUs. XIV International AIDS Conference, Barcelona, July 2002 (abstract MoPeB3258).
10. Puoti M, Zanini B, Bruno R, et al.: Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. HIV Clin Trials 2002;3: 324-332.
11. NIH Consensus Development Conference Statement: Management of hepatitis C 2002. Gastroenterology 2002;123:2082-2099.
12. Lafeuillade A, Hittinger G, and Chapadaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-281.
13. Kakuda T and Brinkman K: Mitochondrial toxic effects of ribavirin. Lancet 2001;357:1803.
14. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, and Sogni P: Mitochondrial toxic effects of ribavirin. Lancet 2001;357:1803.
15. Torriani F, Ribeiro R, Gilbert T, et al.: Early viral dynamics in HIV/HCV infected patients on HCV treatment. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002 (abstract 121).
16. Berg T, Sarrazin C, Herrmann E, et al.: Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.